Shareholder Alert: AF&T Announces That It Has Been Retained to Investigate Claims on Behalf of Investors in Sunesis Pharmaceu...

Abraham, Fruchter & Twersky, LLP (“AF&T” or the “Firm”) has been retained to investigate claims which may be brought on behalf of investors who purchased Sunesis Pharmaceuticals, Inc. (“SNSS” or the “Company”) (NASDAQ: SNSS) during the period of March 12, 2015 through July 23, 2015.

On July 23rd, SNSS surprised investors by announcing that the Food and Drug Administration (“FDA”) would not support the filing of a New Drug Application (“NDA”) based upon the data collected in the Company’s Phase 3 trials because the data did not reach a level of statistical significance. In reaction to this announcement, on July 24th, the stock of SNSS plunged in value by more than 70% to trade at approximately $1.00 per share from its previous closing price of $3.47 per share.

If you would like to discuss this investigation, or if you have any questions concerning your rights as a potential lead plaintiff, you may contact: Jeffrey S. Abraham or Philip T. Taylor of Abraham, Fruchter & Twersky, LLP toll free at [phone], or via e-mail at [e-mail] or [e-mail].

Abraham, Fruchter & Twersky, LLP, which is based in New York and has an office in California, has extensive experience in shareholder and securities class action cases, and the firm has been ranked among the leading class action law firms in terms of recoveries achieved by a survey of class action law firms conducted by Institutional Shareholder Services.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150724005548/en/

Abraham, Fruchter & Twersky, LLPJeffrey S. AbrahamPhilip T. TaylorOne Penn Plaza, Suite 2805New York, N.Y. 10119Telephone: [phone]